Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma

被引:39
作者
Huang, Wen-Wei [2 ]
Tsao, Shih-Ming [5 ]
Lai, Chun-Liang [3 ]
Su, Cheng-Chuan [1 ,4 ,6 ,7 ]
Tseng, Chih-En [4 ,6 ]
机构
[1] Buddhist Dalin Tzu Chi Gen Hosp, Dept Clin Pathol, Chiayi 622, Taiwan
[2] Buddhist Dalin Tzu Chi Gen Hosp, Dept Family Med, Chiayi 622, Taiwan
[3] Buddhist Dalin Tzu Chi Gen Hosp, Dept Chest Med, Chiayi 622, Taiwan
[4] Buddhist Dalin Tzu Chi Gen Hosp, Dept Anat Pathol, Chiayi 622, Taiwan
[5] Chung Shan Med Univ Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan
[6] Tzu Chi Univ, Sch Med, Dept Pathol, Hualien, Taiwan
[7] Tzu Chi Univ, Sch Med, Dept Lab Med, Hualien, Taiwan
关键词
CEA; Cyfra; 21-1; Her-2/neu; lung cancer; pleural fluid; tumour marker; NEURON-SPECIFIC ENOLASE; TUMOR-MARKERS; CANCER; FLUID; UTILITY; CA-19-9; PROTEIN; CA-15-3; TAIWAN; SERUM;
D O I
10.3109/00313021003631320
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Methods: Pleural effusion samples were collected from 41 patients with LAC-MPE, and from 93 with various benign conditions. The diagnostic sensitivity and specificity for Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen (CEA) were evaluated. Cut-off points for these markers are optimally set at 3.6 mu g/L, 60 mu g/L, and 6.0 mu g/L, respectively. Results: Her-2/neu, Cyfra 21-1, and CEA vary in their diagnostic accuracy to differentiate LAC-MPE from benign pleural effusion: 79.85%, 88.81%, and 94.03%, respectively. CEA combined with Cyfra 21-1 increases diagnostic sensitivity to 97.6%, with a specificity of 91.4%. Conclusions: With appropriate cut-off points, CEA currently provides the best diagnostic accuracy. Combining CEA with Cyfra 21-1 increases diagnostic sensitivity to nearly 100%. The results of the present study may help clinicians decide whether to obtain a cytological/histological specimen by invasive means to investigate a possible diagnosis of malignancy.
引用
收藏
页码:224 / 228
页数:5
相关论文
共 29 条
[1]   Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions [J].
Alatas, F ;
Alatas, Ö ;
Metintas, M ;
Çolak, Ö ;
Harmanci, E ;
Demir, S .
LUNG CANCER, 2001, 31 (01) :9-16
[2]   Tumor markers in the diagnosis of malignant serous effusions [J].
Cascinu, S ;
DelFerro, E ;
Barbanti, I ;
Ligi, M ;
Fedeli, A ;
Catalano, G .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1997, 20 (03) :247-250
[3]  
CHANG SC, 1987, J FORMOS MED ASSOC, V86, P672
[4]  
DIBONITO L, 1992, ACTA CYTOL, V36, P329
[5]  
EBERT W, 1994, EUR J CLIN CHEM CLIN, V32, P189
[6]  
Ferrer J, 1999, CANCER-AM CANCER SOC, V86, P1488, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1488::AID-CNCR15>3.0.CO
[7]  
2-Y
[8]   Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies [J].
Fuhrman, C ;
Duche, JC ;
Chouaid, C ;
Abd Alsamad, I ;
Atassi, K ;
Monnet, I ;
Tillement, JP ;
Housset, B .
CLINICAL BIOCHEMISTRY, 2000, 33 (05) :405-410
[9]   Elevated level of carcinoembryonic antigen in nonmalignant pleural effusions [J].
GarciaPachon, E ;
PadillaNavas, I ;
Dosda, MD ;
MirallesLlopis, A .
CHEST, 1997, 111 (03) :643-647
[10]  
Gaspar MJ, 2008, ANTICANCER RES, V28, P2947